Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Rescue Interbody Fusion

Trial Profile

A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Rescue Interbody Fusion

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary) ; Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ALLOB-RIF1
  • Sponsors BioSenic
  • Most Recent Events

    • 11 Jun 2020 According to a Bone Therapeutics media release, the company expects to report 2-year follow-up period results from this study in the second half of 2020.
    • 09 Jun 2020 Status changed from active, no longer recruiting to discontinued.
    • 28 May 2020 This trial has been completed (Global End Date: 25 May 2020), according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top